Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial

Akira Takada, Mikihiro Tsutsumi, Takeshi Okanoue, Nobuo Takada, Masafumi Komatsu, Shigetoshi Fujiyama, Hidetsugu Saito, Hiroshi Nakajima, Hirohito Honda, Masahide Yoshikawa

Research output: Contribution to journalArticle

Abstract

Interferon (IFN) is effective in only a limited number of patients with hepatitis C virus (HCV) type 1 b, indicating that a combination therapy with other antiviral drugs may be essential to obtain better results. In the present study, the effects of a combination therapy with IFN and an antibacterial drug, ofloxacin (OFLX), were analyzed by a multicenter randomized trial. Over 6 million units of various types of IFN were given with 600 mg of OFLX per day to 72 patients with chronic type C hepatitis in 9 different hospitals. The schedule of the combination therapy was categorized into 3 types. In 35 patients who have no IFN therapy previously, IFN was given daily for 2-3 weeks and then 3 times for 21-22 weeks. OFLX was given for 12 weeks from the 8th week of IFN treatment (group I). In 8 patients, who did not respond well to IFN-alone treatment for more than 12 weeks, OFLX was given with IFN for more than 12 weeks (group II). In 14 patients who were non-responders of IFN-alone treatment for 24 weeks, combination therapy was conducted in the same schedule for group I (group III). In group I, 15 of 25 patients with HCV-1 b were responders who were continued normal ALT levels for 6 months after ceasing treatment. In other HCV subtypes, 7 of 10 patients were responders. In group II, responder was found in 5 of 6 patients with HCV-1 b and 1 out of 2 patients with other subtypes. In group III, responders were found in 4 out of 9 patients with HCV-1 b and in 4 out of 5 patients with other subtypes. The incidence of responders was higher than the previously reported values with IFN alone treatment. Severe side effect was found only 3 patients. These results suggest that a combination therapy with IFN and OFLX is an effective treatment for type C hepatitis.

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalJapanese Pharmacology and Therapeutics
Volume24
Issue numberSUPPL. 1
Publication statusPublished - 1996

Fingerprint

Ofloxacin
Chronic Hepatitis C
Interferons
Multicenter Studies
Hepacivirus
Therapeutics
Appointments and Schedules
Hepatitis C
Antiviral Agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Takada, A., Tsutsumi, M., Okanoue, T., Takada, N., Komatsu, M., Fujiyama, S., ... Yoshikawa, M. (1996). Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial. Japanese Pharmacology and Therapeutics, 24(SUPPL. 1), 77-81.

Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial. / Takada, Akira; Tsutsumi, Mikihiro; Okanoue, Takeshi; Takada, Nobuo; Komatsu, Masafumi; Fujiyama, Shigetoshi; Saito, Hidetsugu; Nakajima, Hiroshi; Honda, Hirohito; Yoshikawa, Masahide.

In: Japanese Pharmacology and Therapeutics, Vol. 24, No. SUPPL. 1, 1996, p. 77-81.

Research output: Contribution to journalArticle

Takada, A, Tsutsumi, M, Okanoue, T, Takada, N, Komatsu, M, Fujiyama, S, Saito, H, Nakajima, H, Honda, H & Yoshikawa, M 1996, 'Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial', Japanese Pharmacology and Therapeutics, vol. 24, no. SUPPL. 1, pp. 77-81.
Takada, Akira ; Tsutsumi, Mikihiro ; Okanoue, Takeshi ; Takada, Nobuo ; Komatsu, Masafumi ; Fujiyama, Shigetoshi ; Saito, Hidetsugu ; Nakajima, Hiroshi ; Honda, Hirohito ; Yoshikawa, Masahide. / Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial. In: Japanese Pharmacology and Therapeutics. 1996 ; Vol. 24, No. SUPPL. 1. pp. 77-81.
@article{9071f1a4d7be4d87a46ca015e5c5b2bc,
title = "Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial",
abstract = "Interferon (IFN) is effective in only a limited number of patients with hepatitis C virus (HCV) type 1 b, indicating that a combination therapy with other antiviral drugs may be essential to obtain better results. In the present study, the effects of a combination therapy with IFN and an antibacterial drug, ofloxacin (OFLX), were analyzed by a multicenter randomized trial. Over 6 million units of various types of IFN were given with 600 mg of OFLX per day to 72 patients with chronic type C hepatitis in 9 different hospitals. The schedule of the combination therapy was categorized into 3 types. In 35 patients who have no IFN therapy previously, IFN was given daily for 2-3 weeks and then 3 times for 21-22 weeks. OFLX was given for 12 weeks from the 8th week of IFN treatment (group I). In 8 patients, who did not respond well to IFN-alone treatment for more than 12 weeks, OFLX was given with IFN for more than 12 weeks (group II). In 14 patients who were non-responders of IFN-alone treatment for 24 weeks, combination therapy was conducted in the same schedule for group I (group III). In group I, 15 of 25 patients with HCV-1 b were responders who were continued normal ALT levels for 6 months after ceasing treatment. In other HCV subtypes, 7 of 10 patients were responders. In group II, responder was found in 5 of 6 patients with HCV-1 b and 1 out of 2 patients with other subtypes. In group III, responders were found in 4 out of 9 patients with HCV-1 b and in 4 out of 5 patients with other subtypes. The incidence of responders was higher than the previously reported values with IFN alone treatment. Severe side effect was found only 3 patients. These results suggest that a combination therapy with IFN and OFLX is an effective treatment for type C hepatitis.",
author = "Akira Takada and Mikihiro Tsutsumi and Takeshi Okanoue and Nobuo Takada and Masafumi Komatsu and Shigetoshi Fujiyama and Hidetsugu Saito and Hiroshi Nakajima and Hirohito Honda and Masahide Yoshikawa",
year = "1996",
language = "English",
volume = "24",
pages = "77--81",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Effect of a combination therapy with interferon and ofloxacin for chronic type C hepatitis - A multicenter randomized trial

AU - Takada, Akira

AU - Tsutsumi, Mikihiro

AU - Okanoue, Takeshi

AU - Takada, Nobuo

AU - Komatsu, Masafumi

AU - Fujiyama, Shigetoshi

AU - Saito, Hidetsugu

AU - Nakajima, Hiroshi

AU - Honda, Hirohito

AU - Yoshikawa, Masahide

PY - 1996

Y1 - 1996

N2 - Interferon (IFN) is effective in only a limited number of patients with hepatitis C virus (HCV) type 1 b, indicating that a combination therapy with other antiviral drugs may be essential to obtain better results. In the present study, the effects of a combination therapy with IFN and an antibacterial drug, ofloxacin (OFLX), were analyzed by a multicenter randomized trial. Over 6 million units of various types of IFN were given with 600 mg of OFLX per day to 72 patients with chronic type C hepatitis in 9 different hospitals. The schedule of the combination therapy was categorized into 3 types. In 35 patients who have no IFN therapy previously, IFN was given daily for 2-3 weeks and then 3 times for 21-22 weeks. OFLX was given for 12 weeks from the 8th week of IFN treatment (group I). In 8 patients, who did not respond well to IFN-alone treatment for more than 12 weeks, OFLX was given with IFN for more than 12 weeks (group II). In 14 patients who were non-responders of IFN-alone treatment for 24 weeks, combination therapy was conducted in the same schedule for group I (group III). In group I, 15 of 25 patients with HCV-1 b were responders who were continued normal ALT levels for 6 months after ceasing treatment. In other HCV subtypes, 7 of 10 patients were responders. In group II, responder was found in 5 of 6 patients with HCV-1 b and 1 out of 2 patients with other subtypes. In group III, responders were found in 4 out of 9 patients with HCV-1 b and in 4 out of 5 patients with other subtypes. The incidence of responders was higher than the previously reported values with IFN alone treatment. Severe side effect was found only 3 patients. These results suggest that a combination therapy with IFN and OFLX is an effective treatment for type C hepatitis.

AB - Interferon (IFN) is effective in only a limited number of patients with hepatitis C virus (HCV) type 1 b, indicating that a combination therapy with other antiviral drugs may be essential to obtain better results. In the present study, the effects of a combination therapy with IFN and an antibacterial drug, ofloxacin (OFLX), were analyzed by a multicenter randomized trial. Over 6 million units of various types of IFN were given with 600 mg of OFLX per day to 72 patients with chronic type C hepatitis in 9 different hospitals. The schedule of the combination therapy was categorized into 3 types. In 35 patients who have no IFN therapy previously, IFN was given daily for 2-3 weeks and then 3 times for 21-22 weeks. OFLX was given for 12 weeks from the 8th week of IFN treatment (group I). In 8 patients, who did not respond well to IFN-alone treatment for more than 12 weeks, OFLX was given with IFN for more than 12 weeks (group II). In 14 patients who were non-responders of IFN-alone treatment for 24 weeks, combination therapy was conducted in the same schedule for group I (group III). In group I, 15 of 25 patients with HCV-1 b were responders who were continued normal ALT levels for 6 months after ceasing treatment. In other HCV subtypes, 7 of 10 patients were responders. In group II, responder was found in 5 of 6 patients with HCV-1 b and 1 out of 2 patients with other subtypes. In group III, responders were found in 4 out of 9 patients with HCV-1 b and in 4 out of 5 patients with other subtypes. The incidence of responders was higher than the previously reported values with IFN alone treatment. Severe side effect was found only 3 patients. These results suggest that a combination therapy with IFN and OFLX is an effective treatment for type C hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=9444228351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444228351&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 77

EP - 81

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - SUPPL. 1

ER -